USFDA3 Feb 2026, 08:27 am
SPARC Receives Priority Review Voucher with Sezaby® Approval
AI Summary
Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the United States Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Priority Review Voucher (PRV) associated with the approval of Sezaby®. The PRV is granted to encourage the development of new treatments for rare pediatric diseases and can be redeemed to receive a priority review for a subsequent, separate drug application. This award recognizes the therapeutic value of Sezaby® and provides SPARC with strategic flexibility to accelerate its pipeline development.
Key Highlights
- FDA grants Rare Pediatric Disease Priority Review Voucher (PRV) to SPARC associated with Sezaby® approval.
- PRV encourages development of new treatments for rare pediatric diseases and provides priority review for subsequent drug applications.
- SPARC recognized for the therapeutic value of Sezaby® with this award.
- This award provides SPARC with strategic flexibility to accelerate its pipeline development.
- Sezaby® is a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium powder for injection, approved by FDA for the treatment of neonatal seizures.